多发性硬化患者血清sIL-6R 水平观察

为探讨可溶性白细胞介素－６受体（ｓＩＬ－６Ｒ）在多发性硬化（ＭＳ）发生、发展中的作用，采用双抗体夹心ＥＬＩＳＡ方法，对２８例ＭＳ患者和２５例正常对照组血清ｓＩＬ－６Ｒ水平进行了测定。结果显示缓解－复发型和进展型ＭＳ患者血清ｓＩＬ－６Ｒ水平明显高于正常对照组和良性型组（Ｐ＜０．０５，Ｐ＜０．０１）；而良性型ＭＳ患者血清ｓＩＬ－６Ｒ水平与正常对照组相比，未见明显改变。缓解－复发型ＭＳ患者血清ｓＩＬ－６Ｒ水平随着病情的好转而下降。ｓＩＬ－６Ｒ水平与ＭＳ患者头颅ＭＲＩ上的病灶大小和部位无明显相关性（ｒ１＝０．１２４，Ｐ＞０．０５；ｒ２＝０．０９１，Ｐ＞０．０５）。推测ｓＩＬ－６Ｒ水平的高低可作为判断ＭＳ患者病情变化的指标之一。     

急性早幼粒细胞白血病患者诱导分化治疗前后血清IL—2受体的…

ＥＬＩＳＡ法检测２７例急性早幼粒细胞白血病患者（ＡＰＬ）血清白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果表明ＡＰＬ患者血清ｓＩＬ－２Ｒ高于正常对照（Ｐ〈０．０１），经维甲酸治疗后逐渐降低，但治疗中期患者血清ｓＩＬ－２Ｒ仍高于正常和治疗后（缓解期）患者血清ｓＩＬ－２Ｒ（Ｐ〈０．０５）。治疗后血清ｓＩＬ－２Ｒ虽略高于正常对照。却已恢复正常范围（Ｐ〈０．０５）。同时发现治疗中ＷＢＣ却明显升高，治疗后又下降     

肝癌、肝硬变患者血清肿瘤坏死因子、白细胞介素2和可溶性白细胞介素2受体水平的观察

用放射免疫分析和酶联免疫吸附分析，对２１例原发性肝癌、２０例肝硬变的ＴＮＦα、ＩＬ－２和ｓＩＬ－２Ｒ进行检测，原发性肝癌、肝硬变患者的ＴＮＦα和ｓＩＬ－２Ｒ均显著高于正常组（Ｐ＜０．０１），而ＩＬ－２低于正常组（Ｐ＜０．０１）。     

肝硬化患者血清透明质酸含量与sIL－2R水平的观察

本文用放射免疫测定法及双抗体夹心法测定了２５例健康人，３０例肝硬化患者血清透明质酸（ＨＡ）的含量及可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）水平。结果表明：（１）肝硬化组血清ＨＡ含量及ｓＩＬ－２Ｒ水平均高于对照组（Ｐ值均＜０．０１）；（２）肝硬化组血清ＨＡ与ｓＩＬ－２Ｒ水平间呈正相关关系（ｒ＝０．５１９２，Ｐ＜０．０１）。提示：肝硬化组患者血清ｓＩＬ－２Ｒ水平增高与肝损害程度有关，可能是由于肝细胞受损而对ＳＩＬ－２Ｒ清除能力降低所致。     

活动性肺结核患者血清sIL－2R与抗PPD抗体的相关性

应用ＥＬＩＳＡ检测了正常人和肺结核患者的血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）和抗ＰＰＤ抗体水平。结果表明，活动性肺结核患者的血清ｓＩＬ－２Ｒ和抗ＰＰＤ抗体呈正相关（γ＝０．４３３，Ｐ＜０．００１），而且两者的水平明显高于正常对照组；抗ＰＰＤ抗体阳性的活动性肺结核患者血清中ｓＩＬ－２Ｒ浓度明显高于抗体阴性患者，提示血清ｓＩＬ－２Ｒ浓度测定可以反映肺结核患者细胞免疫功能状态。     

原发性肝癌患者手术治疗前后检测可溶性白细胞介素2受体和肿瘤坏？…

应用双抗体酶联夹心法和放射免疫分析法检测了３０名正常人和３３例原发性肝癌患者血清中ｓＩＬ－２Ｒ和ＴＮＦ含量，结果表明：原发性肝癌患者手术前ｓＩＬ－２Ｒ，ＴＮＦ非常显著地高于正常人（Ｐ〈０．００１，Ｐ〈０．０１）；术后２周，血清ｓＩｌ－２Ｒ与正常人比较有差异（Ｐ〈０．０１），而ＴＮＦ则无差异（Ｐ〉０．０５），ＡＦＰ含量高低与ｓＩｌ－２和ＴＮＦ含量无关（ｒ＝０．３８２６，０．３７２５；Ｐ〉０．０５）。     

活动性肺结核患者血清sIL－2R与抗PPD抗体的相关性

应用ＥＬＩＳＡ检测了正常人和肺结核患者的血清可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）和抗ＰＰＤ抗体水平。结果表明，活动性肺结核患者的血清ｓＩＬ－２Ｒ和抗ＰＰＤ抗体呈正相关（γ＝０．４３３，Ｐ＜０．００１），而且两者的水平明显高于正常对照组；抗ＰＰＤ抗体阳性的活动性肺结核患者血清中ｓＩＬ－２Ｒ浓度明显高于抗体阴性患者，提示血清ｓＩＬ－２Ｒ浓度测定可以反映肺结核患者细胞免疫功能状态。     

肝炎肝硬化患者血清sIL—6R和sgp130变化的研究

为了探讨肝炎肝硬化（ＨＣ）患者血清可溶性白介素６受体（ｓＩＬ－６Ｒ）和可溶性ｇｐ１３０（ｓｇｐ１３０）含量的变化及其临床意义，运用酶联免疫吸附法检测了３４例ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐｌ３０含量。结果表明：①活动性和静止性ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平均高于正常对照（Ｐ＜０．０１），ｓＩＬ－６Ｒ／ｓｇｐ１３０比值ＨＣ患者低于正常人，活动性ＨＣ患者低于静止性ＨＣ患者（Ｐ＜０．０１）；②血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平之间呈正相关（ｒ＝０．４１７，Ｐ＜０．０５），ｓＩＬ－６Ｒ、ｓｇｐｌ３０水平与血清Ｂｉｌ－Ｔ水平间亦呈正相关（分别为ｒ＝０．４７４，ｒ＝０．４８２，Ｐ＜０．０１），而与血清ＡＬＴ水平无明显相关性（分别为ｒ＝０．１９３，ｒ＝０．１５２，Ｐ＞０．０５）。提示：血清ｓＩＬ－６Ｒ、ｓｇｐ１３０与ＨＣ的病情演变有关     

IL—2和sIL—2R在哮喘发病中的意义探讨

为了探讨ＩＬ－２和ｓＩＬ－２Ｒ在哮喘发病中的意义，对３６例哮喘患者外周血单个核细胞诱生ＩＬ－２水平和血浆ｓＩＬ－２Ｒ水平进行了检测，同时以支气管炎患者与正常人作对照，结果表明，ＰＢＭＣ诱生的ＩＬ－２活性哮喘组高于正常对照组（Ｐ＜０．０５）；血浆ｓＩＬ－２Ｒ水平哮喘组高于支气管炎和正常组（Ｐ＜０．０１），后两者差异无显著性。以上结果表明，哮喘发病中存在着Ｔ细胞的活化，ＩＬ－２／ＩＬ－２Ｒ在哮喘发病中     

细胞因子水平与晚期胃癌患者治疗及预后相关研究

本文报道了２４９例晚期胃癌（Ⅲ～Ⅳ期）患者外周血单个核细胞（ＰＢＭＣ）产生ＩＬ－２水平及ＩＬ－２Ｒ表达，外周血清中ｓＩＬ－２Ｒ浓度与ＰＢＭＣ被ＰＨＡ－Ｐ诱生后产生ＩＦＮ－γ活性；并探讨了姑息性手术、化疗和中药治疗对晚期胃癌患者细胞免疫调节因子水平的影响。结果发现：晚期胃癌患者外周血ＰＢＭＣ产生ＩＬ－２及ＩＦＮ－γ能力及ＩＬ－２Ｒ表达均显著低于早期胃癌患者和正常对照组水平（Ｐ＜０．０１）；ｓＩＬ－２Ｒ水平前者明显低于后二者（Ｐ＜０．０１）。姑息手术治疗尽管对晚期胃癌患者的ＩＬ－２、ＩＬ－２Ｒ和ＩＦＮ－γ水平无显著影响，但可降低其ｓＩＬ－２Ｒ水平；而扶正抗癌冲剂则可是显著提高患者术后ＩＬ－２及ＩＦＮ－γ水平和ＩＬ－２Ｒ表达，同时降低ｓＩＬ－２Ｒ水平（Ｐ＜０．０１）；化疗有效晚期患者，则可导致其ｓＩＬ－２Ｒ水平下降，无效者则ｓＩＬ－２Ｒ水平无改变或继续升高。三年随访发现，晚期胃癌患者，术前ＩＬ－２产生水平高于１００Ｕ／ｍｌ，同时ｓＩＬ－２Ｒ水平低于１０００Ｕ／ｍｌ者，其三年生存率高。因而，这项研究对晚期胃癌治疗疗效判断及预后评价有指导意义。     

普乐可复对难治性肾病综合征患者血清IL-2、sIL-2R的影响及其临床意义

目的:研究普乐可复(FK506)对难治性肾病综合征患者血清IL-2、sIL-2R的影响及其临床意义。方法:应用酶联免疫吸附法检测难治性肾病综合征患者经普乐可复治疗前后血清IL-2、sIL-2R水平变化,并监测患者24小时尿蛋白、血浆白蛋白、血脂的变化。结果:难治性肾病综合征患者经普乐可复治疗前血清IL-2、sIL-2R水平均显著高于正常对照组(P<0.05)。治疗后血清IL-2、sIL-2R水平较治疗前明显下降(P<0.05)。治疗前24小时尿蛋白水平显著高于正常对照组(P<0.01),血浆白蛋白显著低于正常对照组(P<0.01),血脂水平显著高于正常对照组(P<0.01);与治疗前比较,治疗后24小时尿蛋白水平显著下降(P<0.05),血浆白蛋白水平显著升高(P<0.01),血脂水平显著下降(P<0.05)。治疗后组与正常组比较,除IL-2外,余各项指标均无显著性差异(P>0.05)。结论:在难治性肾病综合征患者体内存在IL-2、sIL-2R的异常,普乐可复对其有明确的抑制作用,从而调节T细胞活性,有效降低24小时尿蛋白,提高血浆白蛋白含量,降血脂,缓解难治性肾病综合征的病情。     

本草九代对慢性迁延性肝炎患者血清可溶性白细胞介素2受体水平的调节作用

用ELISA方法检测了29名慢性迁延性肝炎患者和18名健康献血员血清可溶性白细胞介素2受体(sIL-2R)水平,同时进行了血清IL-2与sIL-2R的相关分析。结果发现,正常人sIL-R为147±72.1u/ml,而慢性迁延性肝炎病人sIL-2R显著升高(210.5±84).GWe治疗3个月后sIL-2水平显著下降(185.8±79);同时发现IL-2水平与sIL-2R 有一定相关性。上述结果提示GWe具有调节机体IL-2功能的独特作用。     

Racial Variation in Serum-Soluble Interleukin-2 Receptor Levels: A Population-Based Study of Healthy Smokers and Nonsmokers

To investigate the influence of race and cigarette smoking on serum levels of soluble interleukin-2 receptors (sIL-2R), we studied a population-based cohort of 282 white and 173 black adults, ages 20-69 years. Serum sIL-2R concentrations in this healthy population ranged from 146 to 2623 U/ml. Whites had significantly higher sIL-2R levels than, blacks (455 versus 365 U/ml; P < 0.001), and cigarette smokers had significantly higher levels than nonsmokers (508 versus 420 U/ml; P = 0.01). White smokers had the highest levels (550 U/ml); white nonsmokers and black smokers had intermediate levels (455 and 450 U/ml, respectively); and black nonsmokers had the lowest levels (365 U/ml). Smoking cessation appeared to normalize sIL-2R levels; exsmokers who had not smoked for at least 2 years had sIL-2R levels similar to those of never smokers. These data demonstrate the wide range of serum sIL-2R concentrations found in normal healthy adults and the significant influence of race and cigarette smoking. Further investigation of this natural heterogeneity may provide insights into the mechanisms underlying genetic and environmental influences on this important immunologic parameter.     

Soluble interleukin-2 receptors in plasma cell dyscrasias

Levels of the soluble form of the interleukin-2 receptor (sIL-2R) were evaluated in the peripheral blood of 69 patients with plasma cell dyscrasias. A close relationship was seen between serum sIL-2R levels and clinical features. Among patients with normal BUN and creatinine levels, the mean (+/- 1SD) level of sIL-2R in 44 patients with multiple myeloma (MM) was higher than that of normal controls (457 +/- 227 U/ml vs 288 +/- 124 U/ml, P = 0.01). The mean level of sIL-2R in eight patients with primary macroglobulinemia was 722 +/- 251 U/ml. In MM, those with active or refractory disease showed a significantly higher mean level of sIL-2R than those in the remission phase (577 +/- 240 U/ml vs 335 +/- 103 U/ml, P = 0.01). There was a negative correlation between sIL-2R and hemoglobin levels in MM patients (r = -0.45, P = 0.01). Five patients with complications of renal insufficiency had elevated levels of sIL-2R. In a longitudinal study of a patient with plasmacytoma and an extremely high sIL2-R level, the sIL-2R level showed a strong relationship with tumor burden. Patients with high sIL-2R levels generally had a poor prognosis than those with normal levels. Thus a high sIL-2R level may be an indicator of a poor prognosis in MM.     

重症肌无力血清sIL-2R和AchR-ab水平变化的研究

本文对４０例健康成人和４０例不同临床类型的重症肌无力（ＭＧ）病人（全身型和眼肌型），进行了血清可溶性白细胞介素２受体（ｓＩＬ-２Ｒ）和乙酰胆碱受体抗体（ＡｃｈＲ-ａｂ）检测。结果发现全身型和眼肌型ＭＧ患者的ｓＩＬ-２Ｒ明显高于正常人（Ｐ＜０．００１），而全身型的ｓＩＬ-２Ｒ明显高于眼肌型（Ｐ＜０．０５）。ＡｃｈＲ-ａｂ阴性组的ｓＩＬ-２Ｒ明显高于ＡｃｈＲ-ａｂ阳性组（Ｐ＜０．０５）。ｓＩＬ-２Ｒ与ＡｃｈＲ-ａｂ之间经相关性分析，相关系数为-０．４２０８，Ｐ＜０．０５，呈明显负相关。     

急性早幼粒细胞白血病患者诱导分化治疗前后血清IL-2受体的变化及意义

ELISA 法检测27例急性早幼粒细胞白血病患者(APL)血清白细胞介素2受体(sIL-2R)水平.结果表明APL 患者血清sIL-2R 高于正常对照(P<0.01),经维甲酸治疗后逐渐降低,但治疗中期患者血清sIL-2R 仍高于正常和治疗后(缓解期)患者血清sIL-2R(P<0.05)。治疗后血清sIL-2R 虽略高于正常对照。却已恢复正常范围(P<0.05)。同时发现治疗中WBC 却明显升高,治疗后又下降,L-CFU 数随治疗逐渐降低并与病情同步变化。经相关分析,L-CFU 与血清sIL-2R 成正向相关(r=0.737)(P<0.01),而与WBC总数无明显相关性(P>0.05)。     

Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced

We have investigated the association of the recently identified IL6R polymorphisms with the serum levels of soluble IL-6 receptor (sIL-6R). sIL-6R is generated by shedding of the membrane-bound receptor (IL-6Ralpha) or alternative mRNA splicing. In total, 115 healthy volunteers were genotyped, with 70 of them analyzed for sIL-6R levels. Using the PCR/RFLP methods, two important polymorphic sites were selected for genotyping: the 48892A/C (D358A) in exon 9 and the -183G/A in the promoter region. In exon 9, C allele carriers had higher sIL-6R level (P<0.0001) showing that this sequence variation, which corresponds to the proteolytic cleavage site of IL-6Ralpha, strongly influences the serum sIL-6R levels. In the promoter region, G allele carriers had lower sIL-6R levels (P<0.0082) compared with the A allele carriers. This could be attributed to the linkage disequilibrium (D'=0.54, chi2=51.3, P<0.0001) between the -183G/A and the 48892A/C gene polymorphisms.     

Monitoring of disease activity by measurement of inflammatory markers in atopic dermatitis in childhood

Serum levels of soluble interleukin-2 receptor (sIL-2R), intercellular adhesion molecule-1 (ICAM-1), endothelial leukocyte adhesion molecule (ELAM-1), and eosinophil cationic protein (ECP) were measured in 20 patients with atopic dermatitis before and after 4 days'treatment with prednisolone p.o. as well as in 16 healthy, nonatopic controls. Before steroid treatment, patients with atopic dermatitis demonstrated significantly higher serum levels of sIL-2R, ICAM-1, and ECP than healthy controls (P<0.001), whereas ELAM-1 levels were not different between the groups. After 4 days of steroid treatment, clinical improvement was associated with a decrease of sIL-2R (P<0.003), ICAM-1 (P<0.004), and ECP serum levels (P<0.003), but ELAM-1 levels remained unchanged. Both serum ECP and slL-2R levels were significantly correlated with disease severity before as well as after steroid treatment. Changes of sIL-2R concentrations were strongly related to the changes of ECP levels. In addition, changes of serum sIL-2R and ECP levels in percentage were correlated with clinical improvement. These results indicate that the determination of sIL-2R and ECP serum levels may be useful in monitoring disease activity in atopic dermatitis in childhood, especially in treatment trials.     

ELISA检测可溶性白细胞介素2受体夹心法的临床应用及其评价

应用双单克隆抗体夹心法ＥＬＩＳＡ对甲型肝炎、肾综合征出血热、小儿呼吸道合胞病毒感染以及肾移植术后患者等血清中可溶性白细胞介素２受体（ｓＩＬ２Ｒ）进行了定量检测，并对该方法的敏感性、重复性等参委大进行了对比观察。结果表明，该方法敏感性高、特异性强．重复性好，变异率低于国外同类产品，所检测的临床疾病ｓＩＬ－２Ｒ水平的变化与文献报道相符，并与病情、病程相关性良好，可用于基础和临床免疫学研究。     

分泌性中耳炎中耳积液和血清中sIL－2R水平的初步研究

应用酶联免疫吸附法（ＥＬＩＳＡ）对３０例正常人血清（对照组）和６０例分泌性中耳炎患者（ＳＯＭ组）中耳积液和血清中可溶性白细胞介素２受体（ｓＩＬ－２Ｒ）进行了检测。结果示ＳＯＭ组血清ｓＩＬ－２Ｒ水平明显高于对照组，ＭＥＦ中其含量明显高于血清；鼻咽癌组血清及ＭＥＦ中ｓＩＬ－２Ｒ水平明显高于─般ＳＯＭ组；粘液组高浆液组；慢性组高于急性组（均Ｐ＜０．０１）。提示：血清及ＭＥＦ中ｓＩＬ－２Ｒ水平的测定有助于对ＳＯＭ患者免疫状态的评估；ＭＥＦ中ｓＩＬ－２Ｒ可能主要由局部中耳粘膜产生；ＭＥＰ中高浓度的ｓＩＬ－２Ｒ存在可能是ＳＯＭ迁延不愈的─个原因。